Open access
Environmental Microbiology
Research Article
4 December 2023

Environmental surveillance of fungi and susceptibility to antifungal agents in tertiary care hospitals

ABSTRACT

This study aimed to evaluate the epidemiology of fungi in environment of tertiary care hospitals and their susceptibility patterns to seven antifungal agents for controlling and preventing fungal infections in patients. Environmental samplings on the surfaces of different parts of hospitals were collected from four university-affiliated teaching hospitals in Iran. Routine and molecular procedures identified isolated fungi, and antifungal susceptibility tests were performed in vitro. Of the 400 samples, 152 presented positive culture results, and 193 fungal species were isolated. Mold fungi accounted for 59.1% (115 species) of isolates. Most isolated fungal species in descending order were 22 Aspergillus flavus (11.4%), 21 Candida albicans (10.9%), 17 Mucor species (8.8%), 16 Penicillium species (8.3%), 16 Candida famata (8.3%), 15 Alternaria species (7.8%), 13 Fusarium species (6.7%), 11 Candida parapsilosis (5.7%), and 10 Aspergillus niger sensu stricto (5.2%). The isolated Aspergillus species revealed relatively low susceptibility to itraconazole and posaconazole with MIC90 values of 8 µg/mL. The MIC90 values of amphotericin and luliconazole in Candida species were 0.5 and 0.064 µg/mL, respectively. In this study, different species of filamentous and yeast fungi with varying susceptibility to antifungal agents were reported from the environment of the studied hospitals.

IMPORTANCE

Saprophytic fungi can cause nosocomial infections in high-risk patients. These infections are related to high mortality and cost. In the current study, different species of filamentous fungi and yeast were isolated from the environment of the studied hospitals. Some species were resistant to antifungal drugs. We suggest that the future work concentrates on the relationship between the level/quantification of saprophytic contamination in the environment of hospitals and fungal infections in patients.

INTRODUCTION

Saprophytic fungi like Mucorales, Aspergillus, Candida, and Fusarium species can cause outbreaks of nosocomial infections in high-risk patients by transferring from the hospital environment (1). Fungal infections have been on the rise due to the increased number of immunocompromised patients, such as allogeneic hematopoietic stem cell transplantation recipients, solid organ transplantation, the increasing use of invasive devices (central venous catheters), and newer immunomodulatory agents (2 4). In the United States, Aspergillus (A), Candida (C), and Pneumocystis accounted for >80% of fungal infections diagnosed in hospitalized patients (5). Exposure to Aspergillus spores in hospitals can increase nosocomial aspergillosis in immunocompromised patients (4). In patients with hematologic disorders like leukemia, lung cancer, and non-Hodgkin lymphoma, the mortality rate of aspergillosis was reported to be 13–21% (5). Furthermore, candidiasis was diagnosed in 5% of cancer patients with a 12% mortality rate (5). Nosocomial candidiasis in immunocompromised patients is associated with prolonged hospitalization. The frequency of Candida non-albicans species causing nosocomial infections has increased over the past few decades, which have been more resistant to treatment than Candida albicans (6). Weiner et al. reported that Candida species were considered as the fourth most common pathogen across all healthcare-associated infections (7).
There are reports of the isolation of different species of fungi from hospital environments like floors, beds, countertops, baths, and other surfaces (1, 4). In the present research, the epidemiology of fungi in different parts of hospitals and their susceptibility patterns were investigated, aiming at controlling and preventing fungal infections in high-risk patients.

MATERIALS AND METHODS

Sites and sampling

The study was a prospective observational study, performed from May 2020 to May 2022 in four university-affiliated teaching hospitals in Iran (Shiraz, Yasuj, Sanandaj, and Zahedan). Different departments with high-risk patients [solid organ transplantation, hematology, pediatric oncology, and intensive care unit (ICU) wards] were selected as sampling sites. The environmental samples were collected from sink faucets and/or traps, around the beds of patients, air-conditioning units, nursing trolleys, tube racks, and ventilators by pre-moistened cotton-tipped swabs. A total of 400 samples (100 from each hospital) were collected and inoculated on the plates containing sabouraud dextrose agar (Merck, Darmstadt, Germany) with 50 mg/mL of chloramphenicol (Merck, Darmstadt, Germany).

Fungal identification

All the plates were incubated at 24°C for 7 days. To ensure the purity of the isolated fungi, isolated colonies were re-cultured onto separate sabouraud dextrose agar or potato dextrose agar (Merck, Darmstadt, Germany) plates. Isolated fungi were identified based on colony morphology and microscopic evaluation by lactophenol cotton blue and molecular methods.

DNA extraction

DNA was extracted from yeast species using the lithium acetate–SDS (Sigma, St. Louis, MO, USA) solution (200 mM LiOAc and 1% SDS) and 96% ethanol (Merck, Darmstadt, Germany) according to Lõoke et al. (8). DNA was extracted from young filamentous fungi using the phenol-chloroform method (9). In doing so, isolated mold was grown on sabouraud dextrose broth (Merck, Darmstadt, Germany) and incubated with a shaker (120 rpm) for two (Aspergillus species) to three (slow grower molds species) days at 30°C.

Molecular identification

For the identification of yeast species, ITS1 (5′-TCCGTAGGTGAACCTGCGG-3′) and ITS4 (5′-TCCTCCGCTTATTGATATGC-3′) primers were used as per Mirhendi et al. (10). The PCR products were digested with the MspI (Thermo Fisher Scientific, Vilnius, Lithuania) restriction enzyme. The amplification of filamentous fungi was performed using beta-tubulin gene forward 5′-GGTAACCAAATCGGTGCTGCTTTC-3′ and reverse 5′-ACCCTCAGTGTGACCCTTGGC-3′ primers (9). The PCR products were digested by the AlwI (Thermo Fisher Scientific, Vilnius, Lithuania) restriction enzyme. The lengths of amplified and restriction fragment products and the 50-bp DNA ladder (Sinaclon, Tehran, Iran) were visualized by electrophoresis after running in 1.5% and 2% agarose gels (CinnaGen, Tehran, Iran), respectively, for an hour. Mucorales were identified as isolates through amplification of the D1/D2 region and subsequent sequencing (11). The PCR products of some isolates were identified by sequencing. The obtained data were compared to the NCBI nucleotide database (BLAST; https://blast.ncbi.nlm.nih.gov/Blast.cgi) and deposited in GenBank. Sequences were edited and manually adjusted in MEGA-X software version 11.0.13 (12). A phylogenetic tree was created using the unweighted pair group method with an arithmetic mean algorithm in the same software. The evolutionary distances were computed using the p-distance method, and the bootstrap analyses were run for 1,000 replicates.

Antifungal susceptibility testing

The antifungal susceptibility tests of Candida species to amphotericin B (AMB), fluconazole (FLU), itraconazole (ITR), voriconazole (VRC), posaconazole (POS), luliconazole (LUL), isavuconazole (ISA), and caspofungin (CAS) were performed according to the microdilution Clinical and Laboratory Standards Institute (CLSI) M27, M59, and M60 methods (13 15). Antifungal susceptibility of filamentous fungi to AMB, CAS, VOR, ITR, POS, LUL, and ISA was performed, according to CLSI M38-A2 and M61 documents (16, 17). The powders of VRC, FLU, ITR, and CAS were obtained from Sigma (Sigma, St. Louis, MO, USA), and those of POS and AMB were from Sigma (Sigma, Germany). The concentration ranges of VRC, FLU, POS, ITR, CAS, and AMB were 0.03–16 µg/mL, and those for LUL and ISA were 0.008–8 µg/mL. Candida parapsilosis ATCC 22019 were used as quality controls in the same procedure. Antifungal-free well (positive control) and well without fungus (negative control) were included in each row. The 96-well microdilution plates were incubated at 35°C and read after the time procedure presented for yeasts and molds according to CLSI criteria. The concentration of CAS in filamentous isolates causing visible changes in the morphological structure of the hyphae (round, compact, and branched hyphae) was defined as the minimum effective concentration (MEC). The minimum inhibitory concentration (MIC) endpoint for AMB in both yeasts and mold isolates was the lowest concentration inhibiting visible fungal growth (100% inhibition). The MIC values of azole antifungal agents in mold isolates were the lowest concentration inhibiting visible fungal growth (100% inhibition), and that for yeasts species was the lowest concentration inhibiting visible fungal growth (50% inhibition) compared to positive control well growth.

Statistical analysis

Data of the MIC values were collected in SPSS version 16 (International Business Machines Corp., USA). The MIC/MEC ranges, MIC/MEC50 and MIC/MEC90, and geometrics means (MICGM) for each isolate were calculated.

RESULTS

Of a total of 400 samples, 248 (62%) did not yield fungi. Of the 152 positive samples, 41 samples (27%) presented more than one isolate. The fungi recovered from the hospital environment, including 193 species, are presented in Table 1. Yeast accounted for 40.3% of fungal isolates from hospitals. The most commonly isolated fungal species were 22 Aspergillus flavus (11.4%), 21 C. albicans (10.9%), 17 Mucor species (8.8%), 16 Penicillium species (8.3%; OM219079), 16 Candida famata (8.3%), 15 Alternaria species (7.8%; OM756727), 13 Fusarium species (6.7%; OM219620 and OM756730), 11 C. parapsilosis (5.7%), and 10 Aspergillus niger sensu stricto (5.2%). Candida species were isolated from beds, ventilators, and the tap faucet’s contaminated surface. Mold fungi (Aspergillus and Mucor species) have been isolated from the floors of the rooms and around the doors, windows, and air conditioners. Figure 1 demonstrates the phylogenetic tree of the Aspergillus species isolated from the hospital environment. Most of the strains displayed strong relationships in the bootstrap.
Fig 1
Fig 1 Phylogenetic analysis using the beta-tubulin gene of the isolated Aspergillus species.
TABLE 1
TABLE 1 Fungal species isolated from different units of four university hospitals
Mold fungiFrequency (%)Yeast fungiFrequency (%)
Aspergillus flavus22 (11.4%)Candida albicans21 (10.9%)
Aspergillus niger sensu stricto10 (5.2%)Candida famata16 (8.3%)
Aspergillus fumigatus4 (2.1%)Candida glabrata12 (6.2%)
Aspergillus pseudodeflectus1 (0.5%)Candida guilliermondii6 (3.1%)
Mucor species17 (8.8%)Candida parapsilosis11 (5.7%)
Fusarium species13 (6.7%)Candida tropicalis1 (0.5%)
Acremonium spp.2 (1%)Candida krusei1 (0.5%)
Acremonium fusidioides2 (1%)Candida kefyr4 (2.1%)
Black fungi3 (1.6%)Filobasidium magnum2 (1%)
Epicoccum species3 (1.6%)Naganishia albida2 (1%)
Alternaria species14 (7.4%)Naganishia adeliensis1 (0.5%)
Alternaria conjunctiva1 (0.5%)Naganishia diffluens1 (0.5%)
Penicillium species16 (8.3%)  
Chrysosporium species1 (0.5%)  
Scopulariopsis species6 (3.1%)  
Total (193, 100%)115 (59.7%) 78 (40.3%)
The susceptibility patterns of isolated fungi are exhibited in Table 2. The Aspergillus species isolated expressed relatively low susceptibility to ITR and POS, with MIC90 values of 8 µg/mL. The MIC90 value in CAS in Aspergillus species was 0.064 µg/mL, but this value in filamentous fungi other than Aspergillus was 8 µg/mL in Mucor species, 16 µg/mL in hyaline hyphomycetes (Fusarium and Acremonium species), 8 µg/mL in Scopulariopsis species, and 4 µg/mL in Penicillium species. Voriconazole MIC50 value in Aspergillus species (0.5 µg/mL) was lower than that of hyaline hyphomycetes (2 µg/mL), Mucor species (4 µg/mL), and Scopulariopsis species (4 µg/mL). Dematiaceous fungi are most sensitive to CAS (MEC = 0.5 µg/mL) and LUL (MIC90 = 0.5 µg/mL). Hyaline hyphomycetes and Mucor species exhibited high MIC90 values for all antifungal agents. Penicillium species were sensitive to all antifungal agents except CAS (MEC90 value was 4 µg/mL). Fluconazole and ITR proved to be less active against Candida species, with MIC90 values of 16 µg/mL and 8 µg/mL, respectively. Candida species presented low MIC values for ISA (MIC90 = 0.032 µg/mL) and AMB (MIC90 = 0.5 µg/mL). Caspofungin with an MIC90 value of 4 µg/mL was not an effective antifungal agent against environmental Candida species.
TABLE 2
TABLE 2 Comparison of in vitro activities of antifungal agents (µg/mL) tested against isolated fungal species by CLSI method
SpeciesAntifungalsRangeMIC/MEC50MIC/MEC90MICGM
Aspergillus species (n = 37)Amphotericin B Caspofungin Voriconazole Itraconazole Posaconazole Luliconazole Isavuconazole0.032–8 0.016–0.064 0.125–8 0.016–8 0.064–8 0.008–0.25 0.008–0.1251 0.032 0.5 8 0.25 0.032 0.0322 0.064 1 8 8 0.25 0.0640.627 0.027 0.509 4.317 0.570 0.043 0.023
Candida species (n = 31)Amphotericin B Caspofungin Voriconazole Fluconazole Itraconazole Posaconazole Luliconazole Isavuconazole0.016–1 0.016–4 0.016–8 0.25–32 0.016–8 0.016–4 0.008–4 0.008–20.125 0.064 0.064 2 0.25 0.25 0.25 0.0320.5 4 1 16 8 2 4 0.0320.153 0.128 0.117 2.678 0.437 0.235 0.252 0.064
Hyaline hyphomycetes fungia (n = 17)Amphotericin B Caspofungin Voriconazole Itraconazole Posaconazole Luliconazole Isavuconazole0.125–8 0.016–312 1–8 0.125–16 1–8 0.008–4 0.032–41 8 2 4 4 0.5 12 16 8 4 8 2 40.922 4.346 2.771 4.520 1.703 0.193 0.784
Dematiaceous fungib (n = 21)Amphotericin B Caspofungin Voriconazole Itraconazole
Posaconazole Luliconazole Isavuconazole
0.016–0.5 0.016–32 0.016–8 0.016–8 0.016–2 0.008–0.5 0.008–40.125 0.016 0.5 1 0.5 0.008 0.0642 0.5 1 8 2 0.5 40.126 0.043 0.470 1.003 0.243 0.028 0.135
Mucor (n = 17)Amphotericin B Caspofungin Voriconazole Itraconazole Posaconazole Luliconazole Isavuconazole0.016–4 0.016–16 0.5–16 0.25–16 0.125–16 1–16 0.008–0.50.25 4 4 8 2 4 0.252 8 8 8 8 8 20.410 1.451 4.340 5.543 1.920 3.539 0.241
Penicillium species (n = 16)Amphotericin B Caspofungin Voriconazole Itraconazole Posaconazole Luliconazole
Isavuconazole
0.064–0.125 0.016–8 0.016–0.064 0.25–0.5 0.125–0.5 0.032–1
0.125–1
0.064 0.016 0.064 0.032 0.125 0.5 0.1250.064 4 0.064 0.064 0.250 1 0.50.064 0.015 0.039 0.035 0.136 0.806 0.142
a
Hyaline hyphomycetes in this study included Acremonium and Fusarium species.
b
Dematiaceous fungi in this study included black fungi, Epicoccum and Alternaria species, and Alternaria conjunctiva.

DISCUSSION

Fungi are abundant in our surroundings but few are capable of causing infection in humans. There have been reports on the presence of fungi in public places and hospitals (18 20). Exposure to environmental fungi in immunocompromised patients can cause subclinical to severe fungal infections (21, 22). In the present study, the fungi isolated from the environment of university hospitals were evaluated along with their sensitivity patterns investigated. In India, four major clusters of fungal infections in patients were reported: invasive candidiasis, cryptococcosis, invasive aspergillosis, and mucormycosis with a 43.4% (n = 110) mortality rate on 30 days (23). Rayens et al. in 2018 reported 666,235 fungal infections with an attributable cost of $6.7 billion in the United States (5). The fungi included Candida, Pneumocystis, and Aspergillus infections accounting for 76.3% of diagnosed fungal infections with 81.1% of associated costs. Risks of mortality were more than twice as high in patients infected with fungi as in those without fungal infections (5). Prigitano et al. reported that fungi were isolated from 12% of ICU environmental surfaces sampled, with molds isolated from 70.8%, mainly Aspergillus fumigatus, and yeasts, mainly C. parapsilosis and Candida glabrata, were isolated from 27.1% of positive samples (20). The fungal species reported in the present study are comparable to those recorded in hospital environments in other studies conducted.
In the present study, filamentous fungi like Mucor, Aspergillus, Fusarium, Penicillium, Scopulariopsis species, and dematiaceous fungi (Alternaria and Epicoccum) were isolated from the environment. These fungi are known as saprophytic and found in the soil and decaying organic matter, and can cause nosocomial infections in patients, especially in immunocompromised ones (4). Also, these mycoflora can cause infection in immunocompetent patients (24). Spores enter the human body via inhalation or inoculation of the skin or gastrointestinal mucosa and cause sinopulmonary, pulmonary, and other systemic diseases. These organisms are important fungi causing asthma (19). In a study in Japan, the dust of beddings used in 50 houses was examined for fungal flora. The results showed that the yeasts had the largest isolation rate of mycoflora (isolated from 42/50 houses), followed by Cladosporium, Aspergillus, and Alternaria species (19). In the present study, 59.7% of isolates were mold fungi. Mold fungi are existing in different places (25). Based on the ambient temperature, dryness, and humidity of the air, saprophytic fungi are varying by region.
In a study on environmental surfaces in a tertiary care hospital, the fungi recovered from 62.7% of the swab samples were Aspergillus (A. niger sensu stricto, 25.9%; A. flavus, 17.7%; and A. fumigatus, 12.4%), Zygomycetes, and dematiaceous species (1). Abbasi et al. reported different filamentous fungi, Fusarium, Penicillium, Paecilomyces species, and A. niger sensu stricto, in the indoor and outdoor spaces of hospitals and different departments (26). Candida species are the cause of many severe diseases in the intensive care units of hospitals, and they are one of the most common causes of nosocomial bloodstream infections (4). In the United States, non-albicans Candida species particularly C. glabrata were reported to cause most cases of candidemia (4). In Iran, 598 Candida strains were isolated from clinical samples of 10 tertiary care hospitals, with the most commonly isolated Candida species being C. albicans, followed by C. glabrata and C. parapsilosis (25). Isolated strains of yeasts from dust samples in Japan were Naganishia diffluens species complex and Filobasidium magnum (19). N. diffluens were the yeasts often isolated from human skin. From 401 environmental samples from ICU wards, yeasts were growing in 27.1%, mainly on computers (25%) and floors (10.9%), and C. parapsilosis (42.8%) and C. glabrata (28.6%) were the most isolated species (20). The data reported in this study were consistent with some other studies, i.e., 40.3% of the isolates were yeast fungi.
The sensitivity of yeasts and molds to antifungal agents is different, and species with high MIC values for antifungal agents were reported (25, 27). In a study on fungi isolated from nosocomial infections, increased likelihood of resistance to fluconazole was reported for non-albicans Candida species like C. glabrata (16%), Candida krusei (78%), and Candida guilliermondii (11%) (4). Dabas et al. reported high MIC values for azoles in C. albicans, C. glabrata, C. parapsilosis, A. flavus, A. fumigatus, Rhizopus microspores, Rhizopus arrhizus, and Mucor circinelloides. Also, high MEC values for echinocandins in A. fumigatus, C. glabrata, Candida tropicalis, and C. guilliermondii were reported (23). All Aspergillus species (54 species) isolated from airs in a study by Panagopoulou et al. exhibited low minimum inhibitory or effective concentrations for AMB, micafungin, anidulafungin, POS, ITR, and VOR (1). In the present study, FLU and ITR were revealed to have less activity against Candida species, and many filamentous fungi were resistant to antifungal agents. This finding suggests the need for regular monitoring of clinical microbiological data in each area, which can help better manage and treat patients. The limitation of this study was the limited number of samples. If we could evaluate all parts of the hospitals, the number of isolated species would be higher.

Conclusion

Fungal infections in hospitals are associated with high mortality and cost. In this study, different species of filamentous fungi and yeast were isolated from the environment of the studied hospitals. Some species were resistant to antifungal drugs. We suggest that the future work concentrates on the relationship between the level of saprophytic fungal contamination in the environment of hospitals and fungal infections in high-risk patients.

ACKNOWLEDGMENTS

Our thanks go to Hassan Khajehei for linguistic editing of the manuscript.
The research reported in this publication was supported by the Elite Researcher Grant Committee under the award number 983657 from the National Institute for Medical Research Development (NIMAD), Tehran, Iran.

REFERENCES

1.
Panagopoulou P, Filioti J, Farmaki E, Maloukou A, Roilides E. 2007. Filamentous fungi in a tertiary care hospital: environmental surveillance and susceptibility to antifungal drugs. Infect Control Hosp Epidemiol 28:60–67.
2.
Badiee P, Alborzi A. 2010. Detection of Aspergillus species in bone marrow transplant patients. J Infect Dev Ctries 4:511–516.
3.
Badiee P, Alborzi A. 2011. Invasive fungal infections in renal transplant recipients. Exp Clin Transplant 9:355–362.
4.
Suleyman G, Alangaden GJ. 2016. Nosocomial fungal infections: epidemiology, infection control, and prevention. Infect Dis Clin North Am 30:1023–1052.
5.
Rayens E, Norris KA. 2022. Prevalence and healthcare burden of fungal infections in the United States, 2018. Open Forum Infect Dis 9:fab593.
6.
Jahagirdar VL, Davane MS, Aradhye SC, Nagoba BS. 2018. Candida species as potential nosocomial pathogens—A review. Electron J Gen Med 15.
7.
Weiner LM, Webb AK, Limbago B, Dudeck MA, Patel J, Kallen AJ, Edwards JR, Sievert DM. 2016. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011–2014. Infect Control Hosp Epidemiol 37:1288–1301.
8.
Lõoke M, Kristjuhan K, Kristjuhan A. 2011. Extraction of genomic DNA from yeasts for PCR-based applications. Biotechniques 50:325–328.
9.
Nasri T, Hedayati MT, Abastabar M, Pasqualotto AC, Armaki MT, Hoseinnejad A, Nabili M. 2015. PCR-RFLP on β-tubulin gene for rapid identification of the most clinically important species of Aspergillus. J Microbiol Methods 117:144–147.
10.
Mirhendi H, Makimura K, Khoramizadeh M, Yamaguchi H. 2006. A one-enzyme PCR-RFLP assay for identification of six medically important Candida species. Nihon Ishinkin Gakkai Zasshi 47:225–229.
11.
Sulaiman IM, Jacobs E, Simpson S. 2020. Application of ribosomal internal transcribed spacer 1, internal transcribed spacer 2, and large-subunit D1-D2 regions as the genetic markers to identify fungi isolated from different environmental samples: a molecular surveillance study of public health importance. J AOAC Int 103:843–850.
12.
Kumar S, Stecher G, Li M, Knyaz C, Tamura K. 2018. MEGA X: molecular evolutionary genetics analysis across computing platforms. Mol Biol Evol 35:1547–1549.
13.
CLSI. 2017. M27: reference method for broth dilution antifungal susceptibility testing of yeasts. 4th ed. Clinical and Laboratory Standards Institute.
14.
CLSI. 2017. M60: performance standards for antifungal susceptibility testing of yeasts. 1st ed. Clinical and Laboratory Standards Institute.
15.
CLSI. 2018. M59: epidemiological cutoff values for antifungal susceptibility testing. 2nd ed. Clinical and Laboratory Standards Institute.
16.
CLSI. 2008. M38-A2: reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard. 2nd ed. Clinical and Laboratory Standards Institute.
17.
CLSI. 2017. M61: performance standards for antifungal susceptibility testing of filamentous fungi. 1st ed. Clinical and Laboratory Standards Institute.
18.
Ghasemi F, Hatam GR, Zaravar F, Mardaneh J, Jafarian H, Abbasi P, Khorrami HR, Badiee P. 2019. Investigation of the physical, chemical characteristics and microbial contamination of the indoor swimming pools/Kapali Yuzme Havuzlarinin Fiziksel, Kimyasal Ozelliklerinin ve Mikrobiyal Kontaminasyonlarinin Arastirilmasi. Turkiye Parazitol Derg 43:130–134.
19.
Hashimoto K, Yamazaki F, Kohyama N, Kawakami Y. 2020. Analysis of fungal flora in the dust of bedding in Japanese houses and genetic identification of yeasts isolated from the dust. Biocontrol Sci 25:193–202.
20.
Prigitano A, Perrone PM, Esposto MC, Carnevali D, De Nard F, Grimoldi L, Principi N, Cogliati M, Castaldi S, Romanò L. 2022. ICU environmental surfaces are a reservoir of fungi: species distribution in northern Italy. J Hosp Infect 123:74–79.
21.
Badiee P, Alborzi A, Joukar M. 2011. Molecular assay to detect nosocomial fungal infections in intensive care units. Eur J Intern Med 22:611–615.
22.
Badiee P, Choopanizadeh M, Khosravi A. 2018. Sequence base identification of respiratory mucormycosis. Jundishapur J Microbiol 11.
23.
Dabas Y, Xess I, Pandey M, Ahmed J, Sachdev J, Iram A, Singh G, Mahapatra M, Seth R, Bakhshi S, Kumar R, Jyotsna VP, Mathur S. 2021. Epidemiology and antifungal susceptibility patterns of invasive fungal infections (IFIs) in India: a prospective observational study. J Fungi (Basel) 8:33.
24.
Badiee P, Jafarpour Z, Alborzi A, Haddadi P, Rasuli M, Kalani M. 2012. Orbital mucormycosis in an immunocompetent individual. Iran J Microbiol 4:210–214.
25.
Badiee P, Boekhout T, Haddadi P, Mohammadi R, Ghadimi-Moghadam A, Soltani J, Zarei Mahmoudabadi A, Ayatollahi Mousavi SA, Najafzadeh MJ, Diba K, Salimi-Khorashad AR, Amin Shahidi M, Ghasemi F, Jafarian H. 2022. Epidemiology and antifungal susceptibility of Candida species isolated from 10 tertiary care hospitals in Iran. Microbiol Spectr 10:e0245322.
26.
Abbasi F, Samaei MR. 2019. The effect of temperature on airborne filamentous fungi in the indoor and outdoor space of a hospital. Environ Sci Pollut Res Int 26:16868–16876.
27.
Badiee P, Alborzi A, Shakiba E, Joponi A. 2008. Monitoring on antifungal resistance from clinical Candida species by E-test. Int J Infect Dis 12:e278–e279.

Information & Contributors

Information

Published In

cover image Microbiology Spectrum
Microbiology Spectrum
Volume 12Number 111 January 2024
eLocator: e02270-23
Editor: Kessendri Reddy, NHLS Tygerberg/Stellenbosch University, Cape Town, Western Cape, South Africa
PubMed: 38047700

History

Received: 31 May 2023
Accepted: 25 October 2023
Published online: 4 December 2023

Keywords

  1. environmental fungi
  2. Aspergillus
  3. Candida
  4. Mucorales
  5. nosocomial infection

Data Availability

All data analyzed during this study are included in this article. Further inquiries can be directed to the corresponding author.

Contributors

Authors

Professor Alborzi Clinical Microbiology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
Author Contributions: Conceptualization, Data curation, Investigation, Methodology, Project administration, Resources, Supervision, Validation, Writing – original draft, and Writing – review and editing.
Abdolkarim Ghadimi-Moghadam
Department of Pediatric Infectious Diseases, Emmam Sajjad Hospital, Yasuj University of Medical Sciences, Yasuj, Iran
Author Contributions: Resources, Writing – original draft, and Writing – review and editing.
Habibeh Bayatmanesh
Department of Pediatric Infectious Diseases, Emmam Sajjad Hospital, Yasuj University of Medical Sciences, Yasuj, Iran
Author Contributions: Resources and Writing – review and editing.
Jafar Soltani
Department of Pediatrics, Faculty of Medicine, Kurdestan University of Medical Sciences, Sanandaj, Iran
Author Contributions: Resources, Writing – original draft, and Writing – review and editing.
Ali Reza Salimi-Khorashad
Department of Parasitology and Mycology, School of Medicine, Infectious Diseases and Tropical Medicine Research Center, Zahedan University of Medical Sciences, Zahedan, Iran
Author Contributions: Resources, Writing – original draft, and Writing – review and editing.
Fatemeh Ghasemi
Professor Alborzi Clinical Microbiology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
Author Contributions: Investigation, Methodology, Writing – original draft, and Writing – review and editing.
Maneli Amin Shahidi
Professor Alborzi Clinical Microbiology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
Author Contributions: Investigation, Methodology, Writing – original draft, and Writing – review and editing.
Hadis Jafarian
Professor Alborzi Clinical Microbiology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
Author Contributions: Software, Writing – original draft, and Writing – review and editing.

Editor

Kessendri Reddy
Editor
NHLS Tygerberg/Stellenbosch University, Cape Town, Western Cape, South Africa

Notes

The authors declare no conflict of interest.

Metrics & Citations

Metrics

Note:

  • For recently published articles, the TOTAL download count will appear as zero until a new month starts.
  • There is a 3- to 4-day delay in article usage, so article usage will not appear immediately after publication.
  • Citation counts come from the Crossref Cited by service.

Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. For an editable text file, please select Medlars format which will download as a .txt file. Simply select your manager software from the list below and click Download.

View Options

Figures

Tables

Media

Share

Share

Share the article link

Share with email

Email a colleague

Share on social media

American Society for Microbiology ("ASM") is committed to maintaining your confidence and trust with respect to the information we collect from you on websites owned and operated by ASM ("ASM Web Sites") and other sources. This Privacy Policy sets forth the information we collect about you, how we use this information and the choices you have about how we use such information.
FIND OUT MORE about the privacy policy